Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCH346 dose-ranging study in ALS
NCT00072709Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of omigapil in amyotrophic lateral sclerosis (ALS), sponsored by Novartis. Started Sep 2003; status: completed.
02
Drugs
omigapil
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00072709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072709.